BCL-2 Expression and Prognosis in Childhood Acute Leukemia

References

• Tsujimoto Y, Croce C M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 1986; 83: 5214–5218
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitocondrial membrane protein that blocks programmed cell death. Nature. 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985; 228: 1440–1443
   PubMed Web of Science ®Google Scholar
• Cleary M L., Smith S D., Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bd-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986; 47: 19–28
   PubMed Web of Science ®Google Scholar
• Seto M, Jaeger U, Hockett R D., et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2/Ig fusion gene in lymphoma. EMBO J. 1988; 7: 123–131
   PubMed Web of Science ®Google Scholar
• Dellia D, Aiello A, Soligo D, et al. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood. 1992; 79: 1291–1298
   PubMed Web of Science ®Google Scholar
• Hockenbery D M., Zutter M, Hickey W, et al. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA. 1991; 88: 6961–6965
   PubMed Web of Science ®Google Scholar
• Pezzella F, Tse A GD, Cordell J L., et al. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 1990; 137: 225–232
   PubMed Web of Science ®Google Scholar
• Hanada M, Delia D, Aiello A, et al. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993; 82: 1820–1828
   PubMed Web of Science ®Google Scholar
• Kondo E, Nakamura S, Onoue H, et al. Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridaization. Blood. 1992; 8: 2044–2051
   Google Scholar
• Campana D, Coustan-Smith E, Manabe A, et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood. 1993; 81: 1025–1031
   PubMed Web of Science ®Google Scholar
• McDonnell T J., Deanne N, Piatt F M., et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell. 1989; 57: 79–88
   PubMed Web of Science ®Google Scholar
• Vaux D L., Cory S, Adams J M. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988; 335: 440–442
   PubMed Web of Science ®Google Scholar
• Barry M A., Behnke C A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990; 40: 2353–2362
   PubMed Web of Science ®Google Scholar
• Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 1993; 4: 41–47
   PubMedGoogle Scholar
• Miyashita T, Reed J C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Bensi L, Longo R, Vecchi A, et al. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haemalologica. 1995; 80: 98–102
   PubMed Web of Science ®Google Scholar
• Bladbury D A., Russell N H. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol. 1995; 91: 374–379
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault J P., Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993; 81: 3091–3096
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Kitanaka A, Pui C H., et al. Clinical relevance of bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996; 87: 1140–1146
   PubMed Web of Science ®Google Scholar
• Gala J L., Vermylen C, Cornu G, et al. High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Ann Hematol. 1994; 69: 17–24
   PubMed Web of Science ®Google Scholar
• Mating Z T., MacLean F R., Reid M M., et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol. 1994; 88: 105–109
   PubMed Web of Science ®Google Scholar
• Porwit-MacDonald A, Ivory K, Wilkinson S, et al. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogeneous leukemia. Leukemia. 1995; 9: 1191–1198
   PubMed Web of Science ®Google Scholar
• Schmid I, Uittenbogaart C H., Giorgi J. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry. 1991; 12: 279–285
   PubMedGoogle Scholar
• Pollice A A., McCoy J P., Shackney S G., et al. Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. Cytometry. 1992; 13: 432–444
   PubMedGoogle Scholar
• Tsurusawa M, Fujimoto T. Cell cycle progression and phenotypic modification of Ki67 antigen-negative G1- and G2-phase cells in phorbol ester-treated molt-4 human leukemia cells. Cytometry. 1995; 20: 146–153
   PubMedGoogle Scholar
• Terstappen L WMM, Loken M. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol. 1990; 2: 229–240
   PubMed Web of Science ®Google Scholar
• Aiello A, Delia D, Grazia M, et al. Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry. 1992; 13: 502–509
   PubMedGoogle Scholar
• Reed J C., Tanaka S, Cuddy M. Cell cycle analysis of p26-BCL-2 protein levels in proliferating lymphoma and leukemia cell lines. Cancer Res. 1992; 52: 2802–2805
   PubMed Web of Science ®Google Scholar
• Kondo E, Yoshino T, Nomura S, et al. Bcl-2 regulation in normal resting lymphocytes and lymphoblasts. Jpn J Cancer Res. 1994; 85: 260–265
   PubMedGoogle Scholar
• Gerdes J, Schwab U, Lemke H, et al. Production of mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 13–20
   PubMed Web of Science ®Google Scholar
• Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984; 133: 1710–1715
   PubMed Web of Science ®Google Scholar
• Tsurusawa M. Expression of nuclear antigens PCNA and Ki-67 and cell proliferation in childhood leukemia. Int J Pediat Hematol Oncol. 1996; 3: 115–122
   Web of Science ®Google Scholar
• Oltvai Z N., Milliman C L., Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell. 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Yin X M., Oltvai Z N., Korsmeyer S J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 1994; 369: 321–323
   PubMed Web of Science ®Google Scholar